2Tanis BC,Rosendaal FR.Venous and arterial thrombosis during oral contraceptive use:risks and risk factors.Semin Vasc Med,2003,3(1):69-84.
3Kemmeren JM,Algra A,Meijers JC,et al.Effect of second-and third generation oral contraceptives on fibrinolysis in the absence or presence of the factor V leiden mutation.Blood Coagul Fibrinolysis,2002,13(5):373-381.
6Ojvind Lidegaard, Ellen Lokkegaard, Anne Louise Svendsen, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study [J].BMJ,2009,339: b2890.
7Sharma S, Monga D. Venous thromboembolish during oregnancy and the post-partum period:incidence and risk facters in a large victorian health serviee[J].Australian and New Zeland Journal of Obstetrics and Gynaecology,2008,48:44-49.
8Ying Li, Lifeng Zhou, David Coulter et al. Prospective cohort study of te association between use of low-dose oral contraceptives and stroke in Chinese women. Pharmacoepidemiology and Drug Saffy.2006,15:726-734.
9Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethiny estradiol and drispirenone on premenstrual symptomatology and health-related quality of life[J]. J Repord Med,2008,48:79.
